Determination of Vardenafil in Pharmaceutical Formulation by HPLC Using Conventional C₁₈ and Monolithic Silica Columns

References

• Bischoff , E. 2004 . Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events . Int. J. Impotence Res., Suppl. 1 , 16 : S34 – S37 .
   PubMed Web of Science ®Google Scholar
• Potempa , A. J. , Ulbrich , E. , Bernard , I. and Beneke , M. 2004 . Efficacy of vardenafil in men with erectile dysfunction: a flexible‐dose community practice study . Eur. Urol. , 46 ( 1 ) : 73 – 79 .
   PubMed Web of Science ®Google Scholar
• Hatzichristou , D. , Montorsi , F. , Buvat , J. , Laferriere , N. , Bandel , T. J. and Porst , H. 2004 . The efficacy and safety of flexible‐dose vardenafil (levitra) in a broad population of European men . Eur. Urol. , 45 ( 5 ) : 634 – 641 .
   PubMed Web of Science ®Google Scholar
• Dinsmore , W. 2004 . Treatment of erectile dysfunction . Int. J. STD AIDS , 15 ( 4 ) : 215 – 221 .
   PubMed Web of Science ®Google Scholar
• Goldstein , I. , Young , J. M. , Fisher , J. , Bangerter , K. , Segerson , T. and Taylor , T. 2003 . Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double‐blind placebo‐controlled fixed‐dose study . Diabetes Care , 26 : 777 – 785 .
   PubMed Web of Science ®Google Scholar